Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This was a randomized, double-blind, placebo-controlled, ascending single dose safety, tolerability, and pharmacokinetic study of orally administered EDP-322. This study was conducted at a single site. EDP-322 has a benefit to risk profile that supports testing in target patient populations.
Epistemonikos ID: 892574da32021311d15cab687dd05ac130e67b33
First added on: May 05, 2024